Sunil Sarvaria, MD
Gastroenterology · Murfreesboro, TNNPI 1497772198
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,615 of the $45,509 with a category attached, or 78.3%. Gilead accounts for 89.1% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $15,046 and has fallen 92.0% since, to $1,211 in 2025. Among gastroenterology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 309 payments — averaging $147.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$41K
- AbbVie$2K
- Sanofi$318
- Johnson & Johnson$276
- Takeda Pharmaceuticals U.S.A., Inc.$260
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$242
- plus $1K from 28 others
Across 1 payment — averaging $3898.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$4K
What the payments were for
- Speaking & faculty fees$35,61578%
- Travel & lodging$3,6388%
- Food & beverage$6,18914%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 71 | $40,561 |
| AbbVie(2 entities) | 123 | $2,413 |
| Sanofi | 11 | $318 |
| Johnson & Johnson | 16 | $276 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $260 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $242 |
| Janssen Scientific Affairs, LLC | 2 | $148 |
| Madrigal Pharmaceuticals | 2 | $141 |
| Aimmune Therapeutics, Inc. | 6 | $102 |
| Ferring Pharmaceuticals Inc. | 3 | $91 |
| Regeneron Healthcare Solutions, Inc. | 4 | $90 |
| Nestle Healthcare Nutrition Inc. | 5 | $88 |
| Pfizer | 4 | $71 |
| Ardelyx, Inc. | 4 | $69 |
| Alcresta Therapeutics, Inc. | 1 | $64 |
| Novo Nordisk | 3 | $60 |
| Ironwood Pharmaceuticals, Inc | 3 | $51 |
| Evoke Pharma, Inc. | 2 | $50 |
| Bristol Myers Squibb | 2 | $41 |
| Intercept Pharmaceuticals, Inc. | 2 | $39 |
| Redhill Biopharma Inc. | 2 | $38 |
| Merck | 2 | $35 |
| Shionogi Inc | 2 | $33 |
| Boston Scientific | 1 | $32 |
| Braintree Laboratories, Inc. | 2 | $31 |
| Lucid Diagnostics Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Micro-tech Endoscopy USA, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Fresenius Kabi USA, LLC | 1 | $16 |
| Sandoz | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,509 in reported general payments places this provider in the 90th percentile of 336 gastroenterology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 18 | $27,710 |
| LinzessLinaclotide | 12 | $10,566 |
| Colesevelam Hcl | 14 | $1,773 |
| Budesonide DrBudesonide | 18 | $541 |
| Sucralfate | 26 | $386 |
| Omeprazole | 50 | $266 |
| Famotidine | 39 | $236 |
| Pantoprazole Sodium | 23 | $134 |
| Esomeprazole Magnesium | 11 | $121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,413 | $38,27730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 gastroenterology providers in Tennessee.
Other gastroenterology in Murfreesboro
- Cregan LabordeMurfreesboro$82K
- Robert KnoxMurfreesboro$20K
- Roy HoodMurfreesboro$15K
- Brendan O'HareMurfreesboro$13K
- David SchwartzNashville$1.3M
- Ziad YounesGermantown$1M
- Dawn Borromeo BeaulieuNashville$421K
- Satheesh NairMemphis$349K
- Colin HowdenMemphis$291K
- Sara HorstNashville$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.